Loading...
Please wait, while we are loading the content...
Similar Documents
Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients
| Content Provider | Semantic Scholar |
|---|---|
| Author | Palomino, Aitor Cornejo Vallejo-Illarramendi, Ainara Gonzalez-Pinto, A. Aldama, Ana I. Matute, Carlos |
| Copyright Year | 2006 |
| Abstract | Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients Dear Editors, Brain-derived neurotrophic factor (BDNF), the most abundant neurotrophin in the brain, promotes the growth and maintenance of intercellular connections, serves as a neurotransmitter modulator, and participates in plasticity mechanisms, such as long-term potentiation and learning (Shoval and Weizman, 2005). Consequently, abnormal BDNF signaling can influence neuronal differentiation and synaptic function leading to altered brain development and functioning. The ability of BDNF to cross the blood–brain barrier (Pan et al., 1998) suggests that blood serum BDNF levels may reflect BDNF levels in the brain. However, reports about BDNF levels in the serum of schizophrenic patients have been somewhat inconsistent. Thus, an increase, no change, or a reduction in the concentration of BDNF in the blood of schizophrenics has been reported (Jockers-Scherübl et al., 2004; Pirildar et al., 2004; Toyooka et al., 2002). Post-treatment serum BDNF levels were not significantly different when compared with the baseline levels in schizophrenia patients (Pirildar et al., 2004). In turn, BDNF plasma levels in first-episode bipolar disorder patients have not yet been characterized. Here, we have analyzed the plasma level of BDNF in both first-episode schizophrenia and bipolar disorder patients upon admission to hospital and at various stages during a 1-year follow-up. This study consisted of 48 patients (mean age ± S.E. M., 23.7 ± 1 years) from the health catchment area of Vitoria (Alava, Spain), who experienced a first psychotic episode during the period 2002–2004. This sample of patients represents all first-episode patients that needed hospitalization and gave informed consent (75% of total) to participate in the study. There were no differences in age, gender, or clinical symptoms between patients included and excluded. Diagnoses were made at 12 months using the Structured Clinical Interview for DSM IV, SCID-I. 21 patients were diagnosed with schizophrenia, 14 with bipolar disorder, and the remaining 13 with non-specified psychotic disorders. Patients were treated after the first episode with atypical antipsychotics (62–68%), with lithium or other mood stabilizers together with atypical antipsy-chotics (23–26%), with typical antipsychotics (7–11%), or received no treatment (2–4%). Ranges in each treatment group indicate changes in the drugs administered initially at the onset of symptoms and during the first year of illness. Blood samples were collected upon arrival at the hospital emergency room and at 1, 6, and 12 months later, using glass whole-blood tubes containing K3-EDTA. Plasma was isolated by centrifugation … |
| Starting Page | 321 |
| Ending Page | 322 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/j.schres.2006.05.028 |
| Alternate Webpage(s) | http://www.ehu.eus/neurobiology/data/Palomino-et-al-2006-SchizophrRes.pdf |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0920996406002684 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0920996406002684?dgcid=api_sd_search-api-endpoint |
| Alternate Webpage(s) | http://www.ehu.es/neurobiology/data/Palomino-et-al-2006-SchizophrRes.pdf |
| PubMed reference number | 16829047 |
| Alternate Webpage(s) | https://doi.org/10.1016/j.schres.2006.05.028 |
| Journal | Medline |
| Volume Number | 86 |
| Journal | Schizophrenia Research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
